An AI-Designed Drug Is Moving Toward Approval at an Impressive Clip
Insilico Medicine, a biotechnology company based in New York and Hong Kong, has developed an AI-designed drug, ISM018_055, targeting idiopathic pulmonary fibrosis, a fatal lung disease. The drug has entered Phase II clinical trials, marking a milestone in drug discovery. Insilico utilized AI throughout the drug’s development process with their Pharma.AI platform, significantly accelerating the […]